Article info

Original research
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease

Authors

  1. Correspondence to Dr Gilles R Dagenais, Cardiology, Laval University Heart and Lung Institute, Quebec, Canada; gilles.dagenais{at}criucpq.ulaval.ca
View Full Text

Citation

Dagenais GR, Dyal L, Bosch JJ, et al
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease

Publication history

  • Received December 7, 2020
  • Revised April 23, 2021
  • Accepted April 26, 2021
  • First published May 21, 2021.
Online issue publication 
June 25, 2021

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.